Similarly, glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently including exenatide, liraglutide, dulaglutide, lixisenatide, semaglutide, and paired injectables in combinations with other antihyperglycemic drugs, as a class are increasingly used in the treatment of T2D over the last decade [5–7]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.